Orchid Pharma Ltd. Results

H1FY25 Half Yearly Result Announced for Orchid Pharma Ltd.

Pharmaceuticals company Orchid Pharma announced H1FY25 results H1FY25 Financial Highlights: Sales reached Rs 222.7 crore, with EBITDA at Rs 37.5 crore. Cumulative sales amounted to Rs 467.1 crore, a notable 22% YoY increase compared to H1FY24. EBITDA for H1 rose to Rs 78.6 crore. Manish Dhanuka, Managing Director, Orchid Pharma said: “Our growth is a testament to disciplined operational execution and the momentum from our strategic business development initiatives like the newly launched Orchid AMS. The positive trajectory is proof of our commitment to driving sustainable, profitable growth.”

FY24 Annual Result Announced for Orchid Pharma Ltd.

Pharmaceuticals company Orchid Pharma announced FY24 results: Sales for FY24 were at Rs 819.4 crore, up by 23% YoY. PAT surged 71.60% YoY to Rs 94.7 crore in FY24. A highlight of this quarter has been the progress of Orchid Pharma’s novel drug Enmetazobactam. Speaking on the Q4 results, Manish Dhanuka, Managing Director, Orchid Pharma said, “Our revenues have experienced a significant increase over the past year. We have concentrated on maximizing capacity utilization while maintaining stringent cost controls. The positive outcomes of these initiatives, combined with a robust product pipeline and Capex of more than Rs 800 Crore over the next few years, indicate promising future prospects.”

Q2FY23 Quarterly Result Announced for Orchid Pharma Ltd.

Orchid Pharma announced Q2FY23 results: Revenue jumps 36% QoQ and 36% YoY EBITDA jumps 154% QoQ and 133% YoY Manish Dhanuka, Managing Director, Orchid Pharma, said, “Our revenues have seen a sharp uptick over the past year. We have focussed on increasing capacity utilisations while controlling costs. Owing to all the measures we took, bearing fruit, and a strong product pipeline, the results are a sign of positive things to come."